• ABOUT ELITE
    • Overview
    • Our Facility
    • Management & Key Employees
    • Our Board
    • Careers
  • PRODUCTS
  • PIPELINE
    • Generic
    • Branded
  • TECHNOLOGY
    • Technology Overview
    • How It Works
    • One Bead System
    • Two Bead System
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Shareholder Meeting
    • Governance Documents
    • Investor Contacts
    • Email Alerts
logo image
HOME | CAREERS | CONTACT | NEWS |
Share
Skip to content
  • About Elite
    • Overview
    • Management & Key Employees
    • Our Board
    • Careers
  • Products
  • Pipeline
    • Generic
    • Branded
  • Technology
    • Technology Overview
    • How It Works
    • One Bead System
    • Two Bead System
  • Investor Relations
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Shareholder Meeting
    • Governance Documents
    • Investor Contacts
    • Email Alerts
    • Investor Relations
    • Press Releases
    • Events &
      Presentations
    • SEC Filings
    • Shareholder
      Meeting
    • Governance
      Documents
    • Investor Contacts
    • Email Alerts

Press Releases

 
 PDF   Print   View All
Jul 02, 2010
Elite Pharmaceuticals, Inc. Announces 2010 Fourth Quarter and Year-End Investor Conference Call on Thursday, July 8, 2010
Northvale, New Jersey, Friday, July 02, 2010: Elite Pharmaceuticals, Inc. (OTC:BB: ELTP) today announced the Company will host a conference call with investors on Thursday, July 8, 2010 at 4:15 PM EDT to review quarterly and year-end 2010 results. Company executives will also conduct a question and answer session following their remarks.

To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840

A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until July 22, 2010 by dialing:

Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840

About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Two of Elite’s products, Lodrane 24® and Lodrane 24D®, are marketed by a partner, ECR Pharmaceuticals, for allergy treatment. Elite’s lead pipeline products are novel sustained release oral formulations of oxycodone for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Both products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are in late-stage development. Elite, with partners, also has an ANDA filed with the FDA for a generic equivalent of a pain product and has a generic gastrointestinal drug product in clinical development. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.


Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com


This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10-K, 10-Q and 8-K reports. Elite undertakes no obligation to update any forward-looking statements.
  • Site Map   |  Privacy  |  Terms Of Use
Copyright © Elite Pharmaceuticals Inc. | All Rights Reserved.
ART™: Abuse-Resistant Technology for a safer healthier you.
Back to top

Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window